In a randomized, double-masked Phase 2 trial in neuropathic corneal pain (NCP), patients treated with 0.05% urcosimod showed exploratory, directionally favorable changes in corneal nerve architecture on in vivo confocal microscopy. In a subset analysis (n=4 per arm), the urcosimod group recorded median increases in total nerve fiber count (+2.0 n/0.16 mm², IQR 0.54 to 3.63) and total nerve fiber length (+2.6 mm/mm², IQR 1.55 to 5.67; p=0.057 vs placebo for length), while the placebo group showed median decreases in fiber count (–1.92, IQR –2.79 to –0.04) and length (–1.63 mm/mm², IQR –3.76 to 0.63). The company reports the study also achieved pain reduction, though those data were not detailed in this update.
The core development is OKYO’s release of structural nerve imaging data from its completed 18-patient, placebo-controlled Phase 2 NCP study, adding a mechanistic layer to an indication long dominated by subjective pain measures and heterogeneous phenotypes. Urcosimod, a ChemR23 agonist, is being positioned for both anti-inflammatory and analgesic effects, with the new imaging readouts suggesting potential corneal nerve restoration. While based on a very small subset and an exploratory endpoint, the trends strengthen the program’s biological plausibility ahead of a larger, multicenter trial slated to begin in Q1 2026.
Strategically, this looks like a de-risking move to anchor a registrational path in an area with no FDA-approved therapies and historically high placebo variability on patient-reported outcomes. Objective, anatomy-based endpoints can function as supportive evidence as regulators continue to encourage mechanistic validation alongside clinically meaningful effects. The p=0.057 signal for nerve fiber length, coupled with consistent directionality across count and length, gives OKYO a narrative to justify investment in a scaled study without overcommitting to an unproven biomarker as a primary endpoint. It also differentiates the asset from off-label systemic approaches that lack ocular-specific mechanistic confirmation.
For sites, the operational consequence is the likely expansion of in vivo confocal microscopy into the protocol and the need for standardized image acquisition and centralized reading. Centers with established corneal imaging workflows and neuro-ophthalmic expertise will be advantaged, while general ophthalmology sites may face training and equipment gaps. CROs and imaging vendors should anticipate RFPs that pair pain PRO strategy with ophthalmic imaging core lab capabilities and rigorous data quality plans. Regulators will view these structural measures as supportive but will require clear linkage to pain reduction and durability to weigh expedited pathways. Payers will look for correlation between anatomical improvement and functional benefit to underwrite premium pricing in a niche, high-burden population. For patients, a topical, locally acting therapy with evidence of nerve structural impact would be a meaningful alternative to systemic agents used off-label.
Next, watch how OKYO calibrates endpoint hierarchy and powering. A larger study will need to manage phenotype heterogeneity in NCP, mitigate placebo response, and predefine clinically meaningful change thresholds on pain scales while prospectively validating imaging-readout reproducibility across sites. The company’s plan to start in Q1 2026 creates a long runway; interim protocol disclosures on enrichment strategies, central adjudication, and imaging-read standardization will be telling. The key risks remain the small exploratory dataset and near-significant p-value, which demand replication at scale, and the need to demonstrate durability and functional correlation, not just structural plausibility. If those pieces align, OKYO can credibly pursue regulatory dialogue on an objective–subjective endpoint package; if not, the program risks being trapped in signal-finding without a clear registrational bridge.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
